Immunotherapy of malignant ascites

By | October 24, 2011

Immunotherapy of malignant ascites 1. Sapylin (OK-432) is a heat-treated Su strain Streptococcus.
Intraperitoneal injection of OK-432 can be quick after the neutrophils into the abdominal cavity, followed by ascites macrophages and T lymphocytes increased significantly, thereby killing tumor cells and reduce ascites production. Torisu and other treatment of the preparation with 134 cases of malignant ascites of gastrointestinal origin (10KE, 11 less / week by intraperitoneal injection daily for 6 weeks), the results of ascites disappeared completely in 76 cases, 8 cases of ascites was significantly reduced, reduced abdominal circumference more than 10cm, The total effective rate was 62.7% (84/134), and the patient survival (median 10.2 months) is also higher than the control group 50 cases (mean 3.1 months) was significantly prolonged, which tested positive on peritoneal cytology were more effective. Prompt treatment of OK-432 may be effective agents of malignant ascites.
Immunotherapy of malignant ascites 2. Interferon (INF)
INF intraperitoneal injection of the abdominal cavity can increase the activity of natural killer cells, but its effect on malignant ascites unclear. Treatment with INF-a2b was 10 cases III, N of ovarian cancer with ascites (10MU/m2, 1 times / 2 weeks by intraperitoneal injection of 1 – 4 times), only 5 patients with symptomatic improvement, for 2 – 7 weeks The average survival time of 8.1 weeks (3 – 16 weeks), common side effects include fever (> 38.5 C), abdominal pain.
Khabele other one with INF treatment of non-malignant ascites due to ovarian cancer, 15 cases (10MU /, the intraperitoneal injection of 1 – 2 times), 80% (12/15), ascites decreased recurrence within 30 days, 20% of patients ( 3 / the 1st ascites to reduce and maintain more than 30 days, the average survival time of 3 months (0.5 – 13 months), 47% (7 / 15) survival time more than 3 months. Sartori et al reported treatment of 41 cases with malignant INFa2b ascites, weight 50kg doses were 6MU, body weight> 50kg who 9MU, 1 time / 4 days intraperitoneal injection of 6 times and the results ascites disappeared completely and maintain for 30 days in 12 cases, more than 50% reduction of ascites in 15 cases The total effective rate 65.9%, in which the malignant ascites due to ovarian cancer, the effective rate of 75%.
Immunotherapy of malignant ascites 3. Tumor necrosis factor (TNF) Rath and other recombinant human TNF- (rhTNF-), treatment of primary in the ovary, gastrointestinal tract, liver, breast and uterus refractory malignant ascites in 29 cases, rhTNF- dose 40–350g/m2, 1 week intraperitoneal injection daily for up to 2 months and found 16 cases of ascites disappeared completely in 6 patients decreased significantly (more than 50% reduction), 4 cases of ascites decreased ( less than 50% reduction), no increase in ascites in 1 case, 1 case of ascites increased, and the other 1 case of early treatment due to other causes. However, other studies failed to confirm that Hirte, who the 39 patients with malignant ascites (from ovarian cancer or primary peritoneal cancer) were randomly divided into paracentesis plus rhTNF- release fluid or treatment (60g / time, 1 / intraperitoneal injection per week) groups, the results of 18 cases of subretinal fluid paracentesis ten rhTNF- treatment of ascites in patients with non-complete remission in 1 case or in part, subsided. Recently, China was reported by rhTNF-NC (2 – 2.5MU, 2 times / week for 3 weeks) treatment of 8 cases of malignant ascites effective rate of 50%. It was also reported that rhTNF-NC (2.5 – 3MU, 3 times / week for 2 weeks) for the treatment of malignant ascites effective rate 66.7% (12/18). TNF treatment of malignant ascites is uncertain, pending further research.
Immunotherapy of malignant ascites 4. Interleukin-2ClL-2) is a T cell derived lymphokines, can promote T cell, (/ natural killer cells and lymphokine activated killer cells and macrophages induced by IFN, TNF, exert anti-tumor effect. the domestic application of rhIL-2 was injected intraperitoneally (0.5 Mu / times) Treatment of 52 cases of malignant ascites, ascites that can significantly reduce, reduce the number of red blood cells in the ascites, some of tumor cells negative. Some people with high poly staphylococcin (5000u / time) combined with rhIL-2CO.4Mu / times, 1 times / week intraperitoneally for 4 weeks) treatment of malignant ascites, the effective rate was 82.6% (19/23), and high Poly staphylococcin chemotherapeutic lead (60mg / time) in the treatment no significant difference [85.0% C17/20)]. Recently, Yamaguchi et al reported that use of OK-432 and IL-2 treatment of malignant ascites caused by colorectal cancer in 16 cases, treatment of OK-432 alone in 11 cases, 82% (9 / 11) and effective (ascites decreased cancer cell negative) , and with OK-432 and IL-2 combination therapy in 5 cases are valid.
Immunotherapy of malignant ascites 5. Corynebacterium intraperitoneal injection of Corynebacterium peritonitis may be caused by fibers, and parcels of tumor cells to reduce leakage. Some people have used the treatment of breast and ovarian cancer patients with malignant ascites due to 4 cases, 3 were significantly decreased ascites.

Leave a Reply

Your email address will not be published. Required fields are marked *